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Abstract: Neuronal network oscillations are a unifying phenomenon in neuroscience research, with
comparable measurements across scales and species. Cortical oscillations are of central importance in
the characterization of neuronal network function in health and disease and are inﬂuential in effective
drug development. Whilst animal in vitro and in vivo electrophysiology is able to characterize phar-
macologically induced modulations in neuronal activity, present human counterparts have spatial and
temporal limitations. Consequently, the potential applications for a human equivalent are extensive.
Here, we demonstrate a novel implementation of contemporary neuroimaging methods called phar-
maco-magnetoencephalography. This approach determines the spatial proﬁle of neuronal network os-
cillatory power change across the cortex following drug administration and reconstructs the time
course of these modulations at focal regions of interest. As a proof of concept, we characterize the non-
speciﬁc GABAergic modulator diazepam, which has a broad range of therapeutic applications. We
demonstrate that diazepam variously modulates h (4–7 Hz), a (7–14 Hz), b (15–25 Hz), and c (30–
80 Hz) frequency oscillations in speciﬁc regions of the cortex, with a pharmacodynamic proﬁle consist-
ent with that of drug uptake. We examine the relevance of these results with regard to the spatial and
temporal observations from other modalities and the various therapeutic consequences of diazepam
and discuss the potential applications of such an approach in terms of drug development and transla-
tional neuroscience. Hum Brain Mapp 31:581–594, 2010. V C 2009 Wiley-Liss, Inc.
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There are a range of established in vitro and in vivo ani-
mal methods for directly observing the effects of neuroac-
tive substrates upon neuronal activity over time [e.g.
Cunningham et al., 2003; Takita et al., 2007]. The potential
for an equivalent noninvasive human method, which is
able to resolve the temporal characteristics of spatially dis-
crete neuronal activity as a result of neurochemical manip-
ulation, is extensive. The use of functional neuroimaging
to investigate drug responses has seen modest progress,
largely due to the temporal limitations of the prevalent
neuroimaging techniques. Consequently, the focus has
been upon spatial reconstruction, whilst temporally ori-
ented methods have been generally overlooked [Mehta
and Richell, 2005].
Recent developments in magnetoencephalography
(MEG) facilitate the accurate reconstruction of spatial and
temporal characteristics of brain activity, concordant with
functional magnetic resonance imaging (fMRI) [Singh
et al., 2002] and invasive surgical recordings [Mamelak
et al., 2002], respectively. In this work, we describe a novel
method called ‘‘pharmaco-MEG’’ which can spatially char-
acterize oscillatory modulations as a consequence of drug
action and reconstruct the temporal proﬁle at regions of
interest (ROI). As a proof of concept, we demonstrate its
application to the whole cortex characterization of a well-
described GABAergic modulator of the benzodiazepine
family.
c-Amino butyric acid (GABA) is the predominant inhibi-
tory neurotransmitter in the mammalian brain [Whiting,
2006]. GABAA is the principal receptor subtype in the
human brain and has a diverse subunit composition that
interchangeably incorporates binding sites for many neuro-
active substrates that mediate a variety of neuronal mecha-
nisms [Nutt and Malizia, 2001; Wafford and Ebert, 2006].
The most clinically useful of the GABAA modulators are
those that act upon the benzodiazepine-binding sites, as
reﬂected by their wide use in clinical practice [Alldredge
et al., 2001]. The benzodiazepines have a diverse range of
therapeutic applications: diazepam for example, has an
afﬁnity for several subunits and is prescribed as an
anxiolytic, muscle relaxant, sedative, and anticonvulsant
[Giusti and Arban, 1993]; whereas zolpidem is a1 subunit
speciﬁc and is an effective sedative without the other effects
at typical therapeutic doses [Lavoie et al., 1997].
A number of studies have used EEG and MEG as tools
to study the effects of the benzodiazepines upon neuronal
activity [Baker and Baker, 2003; Fingelkurts et al., 2004;
Greenblatt et al., 1989, 1992, 2004; Jensen et al., 2005; Luc-
chesi et al., 2003; Romano-Torres et al., 2002]. Several stud-
ies make task-dependant observations using, for example,
mismatch negativity [Kasai et al., 2002], motor tasks [Baker
and Baker, 2003], median nerve stimulation [Haueisen
et al., 2000], and eye-closure [Ahveninen et al., 2007].
Whilst others focus upon intrinsic oscillatory changes ei-
ther regionally [Greenblatt et al., 1989, 2004] or focally
[Jensen et al., 2005]. However, while oscillations are a fun-
damental electrophysiological feature and temporal resolu-
tion is the principal advantage of these techniques, the
continuous temporal proﬁle of drug-induced oscillatory
change, until now, has not been demonstrated. The eleva-
tion in beta power as a result of benzodiazepine adminis-
tration is a phenomenon that is well recognized in the
EEG literature. In fact, the dominance of such features in a
clinical setting often precludes an informative assessment.
This elevation in cortical beta is a common feature in
patients prescribed GABAA modulatory medications
[Giusti and Arban, 1993] or where alcohol consumption is
a regular factor [Rangaswamy et al., 2002].
Several studies have investigated the spatial distribution
of benzodiazepine receptors, using autoradiography
[Zezula et al., 1988], immunohistochemistry [Rudolph
et al., 2001], or PET [Chang et al., 2005; Fedi et al., 2006].
Whilst these studies are able to determine the proﬁle of
binding across the cortex, their functional signiﬁcance
remains unclear. Ideally, one would use a technique that
is able to obtain a whole cortex spatial image of neuronal
modulation and reconstruct the temporal proﬁle of all
cortical regions in parallel.
Here, we use contemporary MEG techniques to deter-
mine the spatial distribution of changes in intrinsic neuro-
nal oscillations following the administration of a low dose
of diazepam. We then use group imaging to resolve the
proﬁle that is robust across the participant group and ‘‘vir-
tual electrodes’’ (VEs) to reconstruct the temporal proﬁle
of oscillatory change in ROIs over the period of drug
uptake. We present the pharmaco-MEG proﬁle of diaz-
epam and discuss our ﬁndings in the context of the spatial
distribution compared to receptor-binding studies and the
frequency and temporal proﬁles compared to other electro-
physiology studies. We consider the spatiotemporal and
pharmacodynamic proﬁle with regard to the therapeutic
implications of diazepam and explore the potential advan-
tages of this approach in terms of drug development, neu-
ronal network investigation, and translational research.
MATERIALS AND METHODS
Data Acquisition
A total of eight male subjects (seven right handed), with
a mean age of 37 (range, 30–48) participated in the study;
each of whom gave informed consent in accordance with
the local ethics approval for the study. Participants were
placed into a 275 channel MEG system in a supine posi-
tion, for a duration of 60 min. At the start of the recording
a low dose of diazepam (5 mg) was administered orally in
a polysaccharide cased tablet, allowing delivery of the
drug after 10–15 min [Moolenaar et al., 1980]. MEG data
were acquired in a continuous 60-min recording; at a sam-
pling rate of 600 Hz, with head position determined con-
tinuously throughout the experiment via three-head-
localization coils. Following the MEG recording, the three-
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determined using a Polhemus Isotrack digitization system.
Subsequently, data were coregistered with the individual’s
MRI (see Adjamian et al. [2004a] for details). The 60-min
recording period was divided into six identical epochs of
10 min. During each 10-min period, participants were ver-
bally instructed to perform a simple 30-s isometric contrac-
tion of the right hand to localize the precentral gyrus hand
area, a 30-s period of ‘‘eye closure’’ and two brief (2 min)
visual observation and discrimination tasks (results not
reported here); these tasks served to maintain and conﬁrm
attention throughout and to provide veriﬁable anatomical
localizations (see Placebo Control Experiments). Interleaved
between the 5 min of tasks were 5 min of passive eyes-open
relaxation, which were used in the analyses described here.
Data Analysis
The 5 min of passive eyes-open data from each of the
six periods were used to determine the spatial distribution
of intrinsic neuronal activity change. The initial period
was considered as the baseline period, whilst the subse-
quent periods were regarded as ‘‘drug-active’’ periods.
Data were manually screened for eye blink and movement
artifacts, which were routinely removed before SAM anal-
ysis. SAM analysis was conducted (see Synthetic Aperture
Magnetometry Analysis), comparing each of the ﬁve drug-
active periods separately to the baseline period, thereby
providing spatial reconstructions of the averaged cortical
oscillatory changes at 10-min intervals over the entire 60-
min duration. The SAM method requires that the fre-
quency band of interest is predetermined. Therefore, we
analyzed activity using the classical h (4–7 Hz), a (7–14
Hz), b (15–25 Hz), and c (30–80 Hz) frequency bands, in
addition to analyzing in 10-Hz frequency bands between 1
and 100 Hz to improve the observation of activity distrib-
uted between the classical frequency bands. Subsequent to
the individual SAM analyses, group SAM [Singh et al.,
2002] analysis was applied, which generates an image of
the spatial distribution of activity that is consistent across
the group (see Group SAM Analysis). These loci were used
to determine ROIs, from which the temporal proﬁle of os-
cillatory change was reconstructed in each individual (see
Virtual Electrode Analysis). This approach means that each
participant acts as their own individual control.
Synthetic Aperture Magnetometry Analysis
Analyses of oscillatory power change in this study were
conducted at the source level, at ROIs determined using
the SAM method [Hillebrand et al., 2005]. In brief, SAM
uses a linearly constrained minimum variance beamformer
algorithm [Van Veen et al., 1997] to estimate the electrical
activity in each part of a predeﬁned source space through
a weighted sum of the sensor channels. A spatial ﬁlter is
computed for each source location based on the minimiza-
tion of the output power and with the constraint that the
ﬁlter has unity gain at each location; effectively making
the beamformer a special case of the generalized linear
inverse (or Wiener) solution (Eq. 1). The underlying source
current covariance matrix is diagonal, and the amplitude
of its elements is estimated from the data, rather than sen-
sor-source space geometry as used in weighted minimum
norm solutions. The generalized linear inverse, which
gives the estimate of the distribution of underlying neuro-
nal currents j, is given by
^ j ¼ CjLTC 1
D b (1)
with b the measured ﬁeld vector (1 3 N), CD the data co-
variance matrix (N 3 N), Cj the source current covariance
matrix (M 3 M), L the lead ﬁeld matrix (N 3 M), N the
number of channels, and M the number of elements in the
source space. In the beamformer formulation, the source
current covariance matrix Cj is assumed to be diagonal
and the variance component r2
i corresponding to source
space element i with lead ﬁeld li is estimated from:
r2
i ¼ð l
T
i C 1
D liÞ
 1 (2)
Various parameters can be computed based on the
beamformer output (Eq. 1) for a target location, such as
the Neural Activity Index [Van Veen et al., 1997]. A volu-
metric spatial image of brain activity is created by estimat-
ing such an index of neuronal activity sequentially.
Furthermore, active and passive experimental states can be
deﬁned for each target voxel and statistically comparisons
made of the oscillatory power in predetermined frequency
ranges between these states, forming so-called Statistical
Parametric Maps that highlight brain regions that were
differentially activated between the active and passive
states. Here, our active and periods were deﬁned as the
drug-active (10–60-min postdiazepam) and drug inactive
(0–10-min postdiazepam) periods, respectively. A pseudo-t
statistic for the entire brain was computed for the h (4–
7 Hz), a (7–14 Hz), b (15–25 Hz), and c (30–80 Hz) for
each drug active versus drug passive period. This pro-
vided a complete proﬁle of oscillatory change across the
duration of the experiment for each individual. Following
the identiﬁcation of robust activity across the group (see
Group SAM Analysis), these loci were used for further anal-
ysis using VE reconstruction of activity at these ROIs (see
Virtual Electrode Analysis).
Group SAM Analysis
In order for pharmaco-MEG to be implemented as a suc-
cessful tool for the development of pharmacological mod-
els, it is necessary to establish those changes in neuronal
activity that are consistently present across the participant
group. Group SAM analysis achieves this by normalizing
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et al., 2002], with the same normalization parameters sub-
sequently applied to the corresponding SAM images of
neuronal activity change. This determines the spatial dis-
tribution of oscillatory power change, in predetermined
frequency bands, that are robust across individuals. Here,
we used group SAM analyses to determine loci and fre-
quency bands that showed robust modulation over the pe-
riod of drug uptake. Subsequently, the corresponding
coordinates of peak SAM activity in each ROI and fre-
quency were explored using VE analysis.
Virtual Electrode Analysis
The VE approach makes use of the same constrained
spatial ﬁlter as for SAM analysis, with the beamformer
weights for each location computed for a predetermined
set of coordinates. Here, our coordinates were determined
for each individual SAM peak based upon corresponding
group-SAM analysis. These anatomically discrete ﬂuctua-
tions in a speciﬁc frequency band were visualized by
band-pass ﬁltering the VE data at each location to the rele-
vant frequency band (h, a, b,o rc) to generate a ROI-spe-
ciﬁc envelope of oscillatory power during drug uptake.
Root-mean-square (RMS) values were computed for each
envelope, normalized to maximum for each participant,
and presented as individual and corrected group means
for each ROI.
Placebo–Control Studies
Blinded placebo–control recordings were conducted in
four participants. SAM analysis of drug-active versus
drug-passive periods revealed no observable modulation
of intrinsic oscillatory power at ROI either within or
between participants over the duration of the study con-
sistent with previous study recordings [e.g. Hall et al.,
2004]. To directly compare the envelopes of oscillatory
power in the diazepam and placebo conditions, we used
speciﬁc tasks to identify ROIs in visual and motor cortex
corresponding to observed effects (see Results). Speciﬁ-
cally, we used SAM analysis to identify primary motor
cortex (M1) using ﬁnger movement-related beta oscilla-
tions (e.g. Jurkiewicz et al. [2006]) and visual cortex using
eye-closure-induced alpha oscillations (e.g. Ahveninen
et al. [2007]) and visual stimulus (grating) induced gamma
oscillations (e.g. Hall et al. [2005]) At these loci, the motor
beta, visual alpha, and visual gamma oscillations following
administration of either diazepam or placebo were com-
pared by reconstructing the envelope of the VE power
using the method described in previous sections (Fig. 5).
RESULTS
Consistent with the clinical EEG observations, there
were large scale increases in oscillatory activity, dominated
by the beta band. However, SAM revealed there to be a
broad range of oscillatory changes across several regions
of the cortex. Supplementary to beta frequency increases,
there were increases in both the alpha and gamma
frequencies and decreases in theta frequency. SAM analy-
ses demonstrated that the proﬁle of oscillatory change
showed some variability, with a small number of loci
that were robustly (between drug active periods) present
only at the individual level (Fig. 1); whilst the majority of
loci were robustly represented across the participant
cohort.
Group SAM analysis conﬁrmed the proﬁle of neuronal
oscillatory change, although widespread, could be charac-
terized in terms of region and frequency, with reliability
across the group (Fig. 2). These analyses revealed increases
in a, b, and c power in frontal, temporal, precentral, post-
central, and occipital areas and decreases in frontal theta
power. These changes typically reached their maxima
between 20 and 40 min after drug intake (Fig. 3), consist-
ent with the rapid absorption and bioavailability of oral
diazepam [Moolenaar et al., 1980], after which oscillations
reduced to a level still substantially elevated with respect
to the baseline, consistent with rapid initial elimination
rate, and long half-life [Yamazaki et al., 2007]. Results
from the visual discrimination tasks showed no signiﬁcant
change in participants’ responses to stimuli over the dura-
tion of the experiment, suggesting that the observed
results were not a consequence of attentional modulation.
The results are summarized in Table I and described in
detail below.
Sensorimotor Cortex
The administration of diazepam elicited large power
increases in the beta band (15–25 Hz) in the precentral
gyrus of all participants (Fig. 2F). The peak locus was typi-
cally in the hand region of the motor cortex, veriﬁed by
isometric contraction (Fig. 4). A gradual beta power
increase was observed, accompanied by a transient
increase in gamma power that coincided with maximal
beta power at around 20–30 min (Fig. 3E). These data
show a mean beta power after increase after 60 min of
16.3%   4.21% (P < 0.0005). A SAM peak in the postcen-
tral gyrus was observed in broad-band beta and gamma
(15–80 Hz) frequencies (Fig. 2G), which typically reached
maximum at around 30 min (Fig. 3F). These data show a
mean b–c power increase, after 60 min, of 13.88%   4.62%
(paired t-test P < 0.005).
Occipital Cortex
SAM analysis revealed an increase in alpha (7–14 Hz)
activity bilaterally in occipital cortex in all participants
(Fig. 2D). The spatial localization of the alpha peaks was
consistent with those observed during eye closure (Sup-
porting information Fig. 1), which can be seen as an
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throughout the duration of drug uptake (Fig. 3C). Occipi-
tal alpha power appears to increase gradually over time,
reaching maximum typically at around 30 min, with a
mean alpha power increase after 60 min of 15.83%  
3.60% (paired t-test P < 0.0005). SAM analysis revealed
further large increases in occipital gamma (30–80 Hz)
power bilaterally in the region of primary visual cortex of
all participants (Fig. 2H). This increase was gradual, reach-
ing maximum at  20–30 min and was sustained at
increased amplitude for the full duration (Fig. 3G). These
data show a mean gamma power increase after 60 min of
8.26%   3.61% (paired t-test P < 0.001).
Temporal Cortex
SAM analysis reliably revealed that activity in the mid-
dle temporal cortex was restricted to the alpha frequency
range (Fig. 2E), where power increases typically showed a
gradual power increase, reaching maximum after  30 min
(Fig. 3D). These data show a mean alpha power
increase after 60 min of 9.60%   3.63% (paired t-test P <
0.001).
Frontal Cortex
Frontal regions showed widespread reductions in oscil-
latory power in theta (4–7 Hz) band, which could be local-
ized to a number of distinct regions. Prefrontal regions
showed consistent bilateral reduction in oscillatory power
(Fig. 2C), typically reaching maximal reduction after
 20 min (Fig. 3B). Medial frontal regions showed power
reduction (Fig. 2B), with a similar temporal proﬁle to that
observed in prefrontal regions (Fig. 3A). Finally, a unilat-
eral reduction in theta power in the left middle/inferior
frontal region (Fig. 2A), was evident in ﬁve of the eight
participants (e.g. Fig. 1), although it appeared in the right
hemisphere of one subject; possibly a reﬂection of the
handedness of this participant. These data show a mean
theta power decrease after 60 min of 12.53%   2.32% in
the prefrontal cortex (paired t-test P < 0.0005) and 15.30%
  3.13% in the medial frontal cortex (paired t-test P <
0.0005).
In addition to the reductions in theta power across the
frontal cortex, there were observable increases in gamma
power over the duration of the experiment. These
increases were observed in all participants in bilateral
Figure 1.
Virtual electrode reconstruction of the neuronal activity at peak loci in a representative individ-
ual. Traces reﬂect band pass ﬁltered oscillatory power at peak frequencies over 60 min at loci of
maximal power change, as determined from individual SAM analysis in a representative individual.
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amplitude after 30 min (Fig. 3H). Further frontal gamma
frequency power increases were observed in medial
frontal (Fig. 2J) and inferior frontal (Fig. 2I) regions.
However, the location of these peaks was only reliably
evident in ﬁve of the eight participants (e.g. Fig. 1).
These data show a mean gamma power increase after
60 min of 8.00%   3.21% in the prefrontal cortex (paired
t-test P < 0.005).
Placebo–Control Data
SAM analysis of placebo–control data revealed no peaks
of activity that were robust over the period of placebo
uptake, either within of between participants. Reconstruc-
tion of beta activity in precentral cortex, alpha, and
gamma activity in occipital cortex reveal that there are
intrinsic ﬂuctuations in power over the duration of the
experiment. However, these display no robust or sustained
proﬁle over time and are variable between participants
(Fig. 5).
DISCUSSION
It is a challenge for neuroimaging to reliably character-
ize neuronal activity change in response to neurochemical
modulation. Speciﬁcally, whilst the spatial and temporal
characteristics are readily discernible in isolation, the abil-
ity to observe these features in parallel is of fundamental
importance to optimize application and translation of these
methods. Here, we provide a preliminary solution in the
form of pharmaco-MEG, based upon an established beam-
forming-based approach.
Figure 2.
Group SAM images of oscillatory power change in h (4–7 Hz), a
(7–14 Hz), b (15–30 Hz), and c (30–80 Hz) frequency ranges in
response to diazepam administration. Images displayed are a
comparison of the initial baseline period (0–10 min) and the ﬁnal
drug active period (50–60 min). Hot colors reﬂect an increase
and cool colors a decrease in synchronous power, with pseudo-t
values displayed for the peak loci of each image (green dot);
images are thresholded at 50% of maximum. The panel shows:
unilateral decrease in theta in left middle frontal cortex (A), a
decrease in medial frontal theta (B), bilateral decrease in pre-
frontal theta (C), bilateral increase in occipital alpha (D), bilat-
eral increase in alpha in middle temporal cortex (E), bilateral
increase in beta power in the pre-central gyrus (F), bilateral
increase in b–c in the postcentral gyrus (G), bilateral increase in
occipital gamma (H), bilateral increase in inferior frontal gamma
(I), increase in medial frontal gamma (J), and a bilateral increase
in prefrontal gamma (K). For further details see Table I.
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tration are observed across several cortical regions, vary-
ing in frequency, amplitude, and direction of power
change. The spatial pattern of oscillatory change is consist-
ent with observed GABAA receptor density in both animal
[Pirker et al., 2000; Rudolph et al., 2001] and human [Fedi
et al., 2006; Malizia et al., 1998; Zezula et al., 1988] studies.
Whilst there are numerous levels of complexity between
the receptor and networks of neurons, evidence suggests
that MEG oscillations directly reﬂect receptor-mediated
changes in neuronal ﬁring [Jensen et al., 2005], attributable
to the regional cortical homogeneity, and spatial resolution
of MEG, which affords a direct comparison with local net-
work recordings [Hall et al., 2005].
It seems reasonable to assume that intrinsic oscillations,
observable using MEG, can reﬂect information about
receptor proﬁles in the cortex. However, given that oscilla-
tory changes occur across the frequency range, with spatial
overlap, in opposing directions and with possible involve-
ment of deeper sources, a direct quantiﬁable relationship
between receptor density and oscillatory power appears
indeterminable with the current approach. However, the
Figure 3.
Pharmacodynamic envelopes of oscillatory power change at
ROIs. RMS power in the h, a, b, and c frequency bands at peak
loci. Data are displayed as 1 sample/minute for each individual,
normalized to the maximal power (i), the group-mean power
displayed as 1 sample/minute (ii) and as the group-mean power
change over each 10 min period  1.96 SEM, normalized to the
baseline period (iii). Data are presented from loci that are
consistent across participants and where bilateral or midline
results are observed; all data shown are from the left hemi-
sphere as an example. The data shown demonstrate the phar-
macodynamic proﬁles of: medial frontal theta (A), prefrontal
theta (B), occipital alpha (C), temporal alpha (D), precentral
beta (E), postcentral b–c (F), occipital gamma (G), and prefron-
tal gamma (H).
r Pharmaco-MEG: GABAA Cortical Pharmacodynamics r
r 587 rproﬁle of synchronous power change in the prominent (b–
c) frequency range exhibits strong spatial similarities
when compared with PET receptor occupancy studies (Fig.
6), where frontal, sensorimotor, temporal, and occipital
cortices exhibit highest GABAA receptor binding [Chang
et al., 2005; Fedi et al., 2006]. Here, we observe consistent
changes across these regions, as discussed in further detail
in the following sections.
Sensorimotor Cortex
Sensorimotor beta oscillations are believed to arise in
the primary motor cortex (M1) [Baker et al., 1997; Murthy
and Fetz, 1996], whilst the mu rhythm (10 Hz) is believed
to originate in the somatosensory cortex [Salmelin and
Hari, 1994]. Here, we observe that diazepam administra-
tion increases beta power, without an associated change in
the mu rhythm, consistent with previous ﬁndings [Jensen
et al., 2005]. This suggests that the neuronal population
that mediates sensorimotor mu rhythm is a separate, non-
GABAergically mediated, network to the GABAergically
driven network that generates the motor beta rhythm. The
observation of elevated gamma power in somatosensory
cortex is consistent with the ﬁndings that both somatosen-
sory cortex gamma and motor cortex beta rhythms are
mediated by GABAergic modulation of glutamatergic py-
ramidal cells [Roopun et al., 2006; Yamawaki et al., 2008],
which contribute to the majority of the observed MEG sig-
nal [Murakami and Okada, 2006].
TABLE I. Locations of the peaks of activation in each of the frequency bands identiﬁed in the group SAM images,
amplitude of power change (pseudo-t), and Talairach coordinates
Frequency (Hz) Cortical location Power change (t) Talairach coordinates (x, y, z)
Theta (4–7 Hz) Superior frontal gyrus (left) 4.6 15.1 51.2 36.0
Superior frontal gyrus (right) 3.5  16.1 64.3 24.0
Medial frontal gyrus (central) 6.1 3.0 52.2 36.0
Middle frontal gyrus (left) 2.8  39.2 52.2 31.0
Alpha (7–14 Hz) Inferior occipital gyrus (left) 5.7  33.1  93.4  18.0
Inferior occipital gyrus (right) 6.3 30.1  90.4  15.0
Middle temporal gyrus (left) 2.9  57.2 6.0  12.0
Middle temporal gyrus (right) 3.0 63.2 6.0  24.0
Beta (15–25 Hz) Precentral gyrus (left) 14.2  54.2  6.0 30.0
Precentral gyrus (right) 17.0 57.2  7.0 20.0
Beta/gamma (15–80 Hz) Postcentral gyrus (left) 19.2 60.2  12.2 18.0
Postcentral gyrus (right) 16.8 63.2  24.1 23.0
Gamma (30–80 Hz) Superior frontal gyrus (left) 11.1  23.1 55.2 15.0
Superior frontal gyrus (right) 12.4 18.1 54.2 18.0
Medial frontal gyrus (central) 13.0 6.0 51.2 15.0
Inferior frontal gyrus (left) 15.8  48.2 27.1 6.0
Inferior frontal gyrus (right) 10.6 57.2 18.1  6.0
Middle occipital gyrus (left) 9.4  24.1  84.3 0.0
Middle occipital gyrus (right) 10.2 24.1  84.3 0.0
Figure 4.
Time-frequency representation of activity in the hand-motor
area in response to diazepam uptake. SAM analysis of beta
power during isometric contraction of the right hand used to
localize right primary motor cortex hand area (pseudo-t ¼ 2.9).
The SAM peak (left) used to direct virtual electrode analysis
using time frequency spectrograms (Morlett–Wavelet Mann–
Whitney) to compare the activity in drug active phases with
baseline in a representative individual (note a z-value of 1.96
corresponds to P < 0.05).
r Hall et al. r
r 588 rIn response to limb movement, there is a reduction in
power in both the beta and mu frequencies, believed to be
related to neuronal activation [Pfurtscheller and Berghold,
1989]. Following movement termination, mu rhythm
returns gradually to baseline, whilst beta power consis-
tently exceeds premovement baseline levels [Pfurtscheller
et al., 1996]. This increase in power is suggested to reﬂect
transient inhibition of motor cortex [Salmelin and Makela,
1995] consistent with a recalibration of motor systems fol-
lowing movement [Kilner et al., 1999].
The persistently elevated beta power observed here is
indicative of elevated local inhibitory network activity,
consistent with the muscle relaxant properties of diaz-
epam, and its use in the treatment of centrally mediated
muscular tone disorders [Elkassabany et al., 2006]. This
elevated inhibition is likely to mediate muscular tone via
reduced beta coherence between muscle and motor cortex,
as observed using EMG-EEG measures [Baker and Baker,
2003].
The efﬁcacy of benzodiazipine inhibitory action on
motor-cortical networks [Baker and Baker, 2003; Baker
et al., 1997; Fingelkurts et al., 2004; Jensen et al., 2005] rep-
resents an attractive mechanism for the anticonvulsant
Figure 5.
Placebo-control Data. Envelopes of RMS oscillatory power dur-
ing the 60-min postplacebo administration at functionally derived
SAM peaks. Data show alpha power in the visual cortex deter-
mined from eye-closure induced alpha SAM peak (A and D),
gamma power in visual cortex determined from visually induced
gamma SAM peak (B and E), and beta power in motor cortex
determined from ﬁnger movement induced beta (C and F). The
top panel shows data (1 sample/minute) for four subjects’ pla-
cebo data, while the bottom panel shows group mean over each
10 min period  1.96 SEM for placebo versus diazepam at the
same loci.
Figure 6.
Comparison of pharmaco-MEG and PET. Comparative image of
PET receptor density mapping of benzodiazepine receptors using
[11C]-ﬂumazenil and MEG activity in the b–c (15–80 Hz) fre-
quency range following diazepam administration. This image is
partially composed (left panel) of a modiﬁed image from the
study by Fedi et al. [2006].
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ity, whereby high-frequency neuronal activity results in
seizure and in some cases convulsions, is consistent with a
GABAA receptor-mediated increase in neuronal ﬁring re-
fractory period resulting in reduced ﬁring frequency of
elevated amplitude in sensorimotor cortex. However, the
ubiquitous CNS distribution of GABAA receptors, including
other cortical regions and deeper structures, make it unclear
whether the mechanism of anticonvulsant action mediated
by the benzodiazepines is a focal or distributed process.
The spatial coexistence of beta and gamma activity in
somatosensory cortex, whilst consistent with recent in vitro
ﬁndings [Roopun et al., 2006], contradicts the suggestion
that human beta rhythm measured using MEG is analogous
to gamma rhythm observed in vitro [Jensen et al., 2005];
particularly as beta is observed in M1 in vitro and is
elevated by GABAergic modulation [Yamawaki et al.,
2008]. It is increasingly evident that beta and gamma oscil-
lations are observed both interchangeably [Whittington
et al., 2000] and in parallel [Roopun et al., 2006] in a single
cortical region. Here, we observe that the hand area of the
motor cortex, identiﬁed by isometric contraction [Taniguchi
et al., 2000], is characterized by a progressive elevation in
beta power, with an increase in gamma frequency only at
maximal diazepam concentrations.
Visual Cortex
The predominant oscillation in the visual cortex is the
alpha rhythm, a focus of electrophysiological research
since reported by Berger in 1929. Although the gross dy-
namics of visual alpha are reasonably well deﬁned, the
physiological basis and functional signiﬁcance are not
entirely certain. Alpha is believed to be modulated by a
thalamo-cortico-thalamic reentrant network, governed by
GABAergic neurons of both the thalamus and cortex
[Klimesch et al., 2007]. Alpha oscillations are directly inﬂu-
enced by input to the visual cortex; best demonstrated by
an increase in alpha power during eye closure. Recent
work by Ahveninen et al. [2007] demonstrated a reduction
in occipital alpha power, particularly during eye-closure,
in participants administered the benzodiazepine loreze-
pam. Here, we describe a reduction in eye-closure induced
alpha power change during the diazepam condition (mean
reduction 17.80%) compared to both baseline and placebo
(Figs. 3 and 5; Supporting information Fig. 1). However,
the observed increase in the intrinsic baseline alpha fol-
lowing diazepam administration is, surprisingly, in con-
trast to previous observations using lorazepam,
[Ahveninen et al., 2007; Fingelkurts et al., 2004] or diaz-
epam [Saletu et al., 1988] where reductions in alpha power
were observed. These paradoxical observations are likely
the consequence of dose-dependent variations in speciﬁc-
ity, particularly as the dose of diazepam used here is
lower than those used in previous studies; this is of partic-
ular importance given the overall lack of speciﬁcity of
these drugs for GABA-A subunits. Nevertheless, what
appears to be consistent is that visual alpha oscillations
are under the direct inﬂuence of GABAergic modulation
[Ahveninen et al., 2007; Klimesch et al., 2007].
Gamma oscillations in the primary visual cortex are
observed in both animals [Gray and McCormick, 1996;
Kreiter and Singer, 1996; Logothetis et al., 2001; Siegel and
Konig, 2003] and humans [Adjamian et al., 2004b;
Hadjipapas et al., 2007; Hall et al., 2005; Keil et al., 1999].
Visual gamma is implicated in visual feature integration
[Gray and McCormick, 1996], object recognition [Tallon-
Baudry and Bertrand, 1999], and selective attention [Fell
et al., 2003]. However, an increase in gamma power occurs
in response to basic visual stimuli, such as gratings, and is
directly dependant upon simple characteristics such as
contrast [Hall et al., 2005] and spatial frequency [Adjamian
et al., 2004b; Hadjipapas et al., 2007]. These data suggest
that ongoing gamma oscillations in the primary visual cor-
tex are GABAergically mediated, consistent with recent
observations [Muthukumaraswamy et al., 2009].
Here, we show an increase in the intrinsic gamma
power in primary visual cortex following diazepam, con-
sistent with GABAergic interneuron-modulated drive
[Whittington and Traub, 2003], and with the model sug-
gesting GABAergic modulation of visual gamma [Jensen
et al., 2002]; whilst allowing for the possibility that modu-
lation may also occur in response to more complex cogni-
tively dependant modulations of the visual system [e.g.
Tallon-Baudry and Bertrand, 1999].
Temporal Cortex
The role of increased alpha oscillatory power, observed
here, in the middle temporal cortex is unclear, although
the role of this brain region in memory [Gonsalves et al.,
2005] is of interest with regard to the amnestic properties
of the benzodiazipines and other GABAA modulators.
Alpha modulation is consistent with memory processing
[Pesonen et al., 2007], known to be disrupted at various
stages of encoding and retrieval by GABAergic modulators
such as alcohol [Krause et al., 2002].
Increased temporal lobe alpha activity as a consequence
of GABAergic modulation is consistent with the observed
reduction in temporal lobe benzodiazepine binding in
patients with generalized anxiety disorder [Tiihonen et al.,
1997], for which benzodiazepines are a common therapeu-
tic intervention. Similarly, changes in temporal lobe
GABAA subunit expression in both temporal lobe epilepsy
[Sperk et al., 2004] and absence seizures [Li et al., 2006],
neither involving motor components, suggest that anticon-
vulsant effects via GABAergic modulation may be a glob-
ally mediated mechanism.
Frontal Cortex
EEG studies demonstrate that frontal midline theta
reﬂects elevated anxiety levels, which are reduced
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[Suetsugi et al., 1998], with coincident physiological effects
such as the galvanic skin response [Aftanas et al., 2002].
Reduced frontal theta power, observed here in response to
diazepam is consistent with its anxiolytic properties as
previously reported in the EEG following administration
of the anxiolytic clomipramine [Suetsugi et al., 1998]. Sleep
deprivation, known to reduce anxiety in patients suffering
from anxiety disorders [Pﬂug, 1978], also modulates theta
oscillatory power in frontal regions [Cajochen et al., 1999].
GABAA receptors have an established role in anxiety [Nutt
and Malizia, 2001] with speciﬁc mediation through a2
receptors [Low et al., 2000; Rudolph et al., 2001]. These
receptors are localized to the hippocampi, amygdalae, and
basal forebrain [Fritschy and Mohler, 1995], whose connec-
tivity with the cortex is important in the manifestation of
anxiety. Observations in vivo of elevated hippocampal
theta during ‘‘fear’’ in conditioned animals [Moita et al.,
2003] is supported by human MEG studies demonstrating
event related theta in response to unpleasant visual stimuli
[Nishitani, 2003]. Connectivity between the hippocampi
and prefrontal cortical regions is reﬂected by a phase rela-
tionship at theta frequency [Siapas et al., 2005]. Conse-
quently, modulation of frontal theta, as observed here,
may be an indication of hippocampal activity as a direct
consequence of this phase relationship [Jensen and Lis-
man, 2005].
The observation of spatially coincident changes in theta
and gamma power at several locations of the frontal cortex
is suggestive of involvement of subcortical structures
through an interaction of short- and long-range connectiv-
ity, which appear as a function of scale [von Stein and
Sarnthein, 2000]. Furthermore, spatially colocalized
changes in theta and gamma are observed during memory
paradigms [Burgess and Ali, 2002; Schack et al., 2002], con-
sistent with the amnestic properties observed in the benzo-
diazepines at various doses [Bustos et al., 2006; Krause
et al., 2002]. A recent study by Pesonen et al. [2007] using
EEG, revealed increased theta and decreased alpha and
beta power with increased memory load. Although these
results were not presented in terms of spatial location,
they are consistent with the decreased theta and increased
alpha and beta following administration of an amnestic
drug.
Placebo–Control Data
The placebo–control recordings here offer several useful
insights into the efﬁcacy of pharmaco-MEG as a tool for
further exploration of neuronal activity. First, the clear dif-
ference between diazepam-induced changes in oscillatory
power and placebo control suggest that typically low
doses of a neuromodulator can be differentiated from
intrinsic ﬂuctuations in oscillatory power. Second, whilst
placebo–control experiments do not show any characteris-
tic sustained trend of oscillator modulation over the period
of the experiment, there are clear ﬂuctuations in intrinsic
oscillations over the course of the experiment. This has
potential implications for differentiating lower doses (e.g.
microdoses) of a particular drug. Furthermore, over
shorter durations, the ‘‘natural’’ ﬂuctuations in oscillatory
power may prove more difﬁcult to disentangle from drug-
induced effects. Finally, there is a strong likelihood that
these intrinsic ﬂuctuations are attentionally modulated and
therefore either shorter experiments or more sensitive
measures of attention would be required to avoid or
account for these effects.
CONCLUSION
The principal advantage of this approach is its ability to
reconstruct the temporal proﬁle of local neuronal activity
at any point within the cortex. Therefore, we are provided
with a representation of oscillatory power change in ROIs
during drug uptake. This approach represents a more spa-
tially reﬁned and ﬂexible method of reconstructing the
neural pharmacodynamic proﬁle, than those previously
employed [Greenblatt et al., 2004]. The potential of this
method could be fully realized through the observation of
more speciﬁc therapeutic agents, such as those effective
upon receptor subtypes. Whilst this pharmaco-MEG
approach is based upon the SAM beamforming method, it
is noteworthy to mention that other approaches such as
dynamic imaging of coherent sources are likely to offer
similar outcomes for pharmacological investigation. Phar-
maco-MEG allows us to reconstruct the neuronal activity
in response to pharmacological manipulation at a speciﬁc
region of interest in the brain. This method is ﬂexible,
allowing a ROI to be determined in postprocessing,
thereby offering the potential to characterize the speciﬁc
pharmacodynamic proﬁle of any cortical region. Further-
more, as a direct measure of neuronal activity, it is argu-
ably less susceptible to the vascular, hemodynamic, and
metabolic changes that pose potential difﬁculties for alter-
native pharmacological neuroimaging approaches such as
pharmaco-fMRI.
The continuous high-temporal resolution approach used
here affords the ability to generate accurate pharmacody-
namic proﬁles of a range of similar drugs against which
candidate agents can be compared (see Supporting infor-
mation Fig. 2). Additionally, the time/frequency interrela-
tionship affords us the opportunity to make more accurate
inference about neuronal network activity and the compar-
ison with animal in vitro/in vivo models. Furthermore,
whilst this oral-drug implementation focuses upon
extended durations, IV administration typically elicits an
immediate effect, for which high-temporal resolution is an
essential feature. Finally, whilst this proof-of-concept
focuses on simple measures of oscillatory amplitude, the
potential to extend the VE implementation to investigate
the relationship between cortical regions involved have
great potential.
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potential limitations of the approach that are worthy of
further consideration: First, as we observed with our pla-
cebo–control data, natural drifts in oscillatory power occur
in all frequency bands. These occur unpredictably, without
consistency either within or between participants and
under conditions where attempts were made to maintain
attention; possibly reﬂecting the need for more sensitive
measures of attentional state. Second, spatial homogeneity
is subject to greater variability than other MEG studies as
spatial inhomogeneity exists in both the anatomical struc-
ture and the receptor distribution/density. This is poten-
tially problematic when considered in the context of MEG
source reconstruction and, in particular, group analysis
where such variability can inﬂuence the robustness of
localization. Finally, a consequence of the relatively high-
spatial resolution of the SAM beamforming approach, and
indeed MEG generally, is insensitivity to deeper sources.
The consequence in this case is that it is not possible to
determine the inevitable effects of the drug on deep struc-
tures and, similarly, whether observations are the result of
direct modulation of cortically located receptors or projec-
tions from distal structures; inevitably both are repre-
sented here. An integrative approach, using receptor
density measures, such as PET to guide pharmaco-MEG,
has clear potential to circumvent many of the limitations
discussed earlier. An attractive potential application of the
approach presented here is in drug development. Whilst
determination of the individual therapeutic characteristics
for such a broad-acting drug are not possible in isolation,
a combined approach that determines the shared charac-
teristics of a range of agents with a common therapeutic
application offers a potentially invaluable tool (Supporting
information Fig. 2). Such a tool could provide the informa-
tion necessary to determine the characteristics of an effec-
tive substrate, whilst concurrently identifying potentially
unwanted side effects. Furthermore, it is apparent that
there is wide scope to apply more complex signal-process-
ing methods to investigate the proﬁle of pharmacologically
induced neuronal change and interactions between ROIs;
an approach likely to offer more valuable information
regarding the mechanistic bases of drug action.
This approach provides a method by which to determine
the pharmacodynamic time course of drug action in a spe-
ciﬁc local cortical network, illustrated here by the mean
uptake proﬁles of diazepam (Fig. 3). When combined with
functional task localization, the pharmacodynamic proﬁle
can be determined for a functionally relevant ROI. The
dose of diazepam used in this study was a low-therapeutic
dose that elicited no pronounced therapeutic effects in the
participants tested, yet oscillatory power was increased by
as much as 53% (precentral beta) in some participants. This
raises the questions: what dose is detectable using this
MEG method? And is it possible to detect changes at micro-
dose levels? When combined with a therapeutic proﬁle, the
reduced risk factors associated with subtherapeutic observa-
tions have great potential value in the reﬁnement and test-
ing of potential drug candidates. Finally, this preliminary
work demonstrates the potential of MEG-based techniques
to determine the pharmacodynamic proﬁle of neuronal ac-
tivity in the intact human brain as a consequence of drug
modulation. This approach provides a direct comparator
for animal electrophysiology measures and, consequently,
has the potential to make a strong contribution to transla-
tional neuroscience research.
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